New Horizons – Global Access to Treatment
Dr. Sameer Rastogi and Dr. Yoon-Koo Kang presented "Global Access to Treatment" at New Horizons 2021.
New Horizons – Best Practices: How to Advocate for Better Access
Sarah McGoram, Carolina Goič, Florence Thwagi, Tania Carolina Diaz presented Best Practices: How to Advocate for Better Access at New Horizons 2021.
New Horizons – GIST Research Updates
Dr. Ciara Kelly, Dr. Suzanne George, and Dr. Bruno Vincenzi presented GIST Research Updates at New Horizons 2021.
New Horizons – SDH-deficient GIST Research Update
Dr. Shruti Bhargava, University of California San Diego, presented SDH-deficient GIST Research Updates at New Horizons 2021.
New Horizons – Using Real World Evidence to Impact Future Clinical Trials
Pete Knox of The Life Raft Group presented Using Real World Evidence to Impact Future Clinical Trials and Improve Patient Survival: A Focus on Placebos at New Horizons 2021.
October 2nd GIST DO IT Walk NJ Postponed
The welfare of our members and staff is of utmost importance to us and due to ongoing pandemic, we have decided to take the precaution of postponing our GIST DO IT Walk which was scheduled for October 2nd.
New Treatment Updates for Advanced GIST
This video is about the new treatment updates for advanced GIST. It is presented by William D. Tap, MD.
Management of Metastatic GIST – What to Expect When a Tumor has Spread
This video contains information about the management of metastatic GIST presented by Dr. Aimee Crago.
Conversations with the LRG: Long-Term Survivors
On May 4th the LRG held a lively discussion with three long-term survivors, Erin McBean, John Abrams, and Dr. mOe Anderson. Diagnosed at different stages of life, with different mutations, these GISTers shared how they have thrived with GIST over ten years and counting.
LRG Represented on Panel About Diversity
The National Organization for Rare Disorders (NORD) held a webinar on February 19th, 2021 for NORD member organizations as well as leaders and staff of nonprofits organizations involved in rare diseases including pharma, patients, caregivers, and advocates.